Antiviral drugs: Unapproved uses, dosages, or indications

Clinics in Dermatology

Volumn 20, Issue 5, 2002, Pages 474-480

  Rebora, Alfredo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b Clinica Dermatologica   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; DACARBAZINE; FLUOROURACIL; FOSCARNET; IMIQUIMOD; MEGLUMINE ANTIMONATE; PLACEBO; VALACICLOVIR; ZIDOVUDINE;

ACTINIC KERATOSIS; ALLERGY; BASAL CELL CARCINOMA; BONE MARROW TRANSPLANTATION; BOWEN DISEASE; CLINICAL EXAMINATION; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG SAFETY; EDEMA; EPSTEIN BARR VIRUS; EROSION; ERYTHEMA; ERYTHEMA MULTIFORME; FLU LIKE SYNDROME; HEADACHE; HERPES SIMPLEX VIRUS; HERPES VIRUS INFECTION; HISTOLOGY; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; KERATOSIS; LEISHMANIASIS; MACROPHAGE; MELANOMA; MOLLUSCUM CONTAGIOSUM; MYALGIA; NONHUMAN; PHOTODYNAMIC THERAPY; POROKERATOSIS MIBELLI; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN INDURATION; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; STEVENS JOHNSON SYNDROME; TREATMENT OUTCOME; VIRUS INFECTION; WISKOTT ALDRICH SYNDROME;

EID: 0036757399     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(02)00277-8     Document Type: Article

References (58)

1. Cheriyan S., Patterson R. Recurrent Stevens-Johnson syndrome secondary to herpes simplex a follow up on a successful management program . Allergy Asthma Proc. 17:1996;71-73.
2. Tatnall F.M., Schofield J.K., Leigh I.M. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol. 132:1995;267-270.
3. Katz J., Livneh A., Shemer J., et al. Herpes simplex-associated erythema multiforme (HAEM) a clinical therapeutic dilemma . Pediatr Dent. 21:1999;359-362.
4. Weston W.L., Morelli J.G. Herpes simplex virus-associated erythema multiforme in prepubertal children. Arch Pediatr Adolesc Med. 151:1997;1014-1016.
5. Kerob D., Assier-Bonnet H., Esnault-Gelly P., et al. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy. Arch Dermatol. 134:1998;876-877.
6. Edwards L. Imiquimod in clinical practice. J Am Acad Dermatol. 43:2000;S12-S17.
7. Zabawski E.J. Jr. A review of topical and intralesional cidofovir. Dermatol Online J. 6:2000;3.
8. Bienvenu B., Martinez F., Devergie A., et al. Topical use of cidofovir induced acute renal failure. Transplantation. 73:2002;661-662.
9. Snoeck R., Van Ranst M., Andrei G., et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. [letter] N Engl J Med. 333:1995;943-944.
10. Douglas J., Corey T., Tyring S., et al. A phase I/II study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection. Poster presented at the 4th conference on Retroviruses and Opportunistic Infections, Washington DC, January 22-26. 1997;. Poster #334.
11. Snoeck R., Bossens M., Parent D., et al. A Double-Blind, Placebo-Controlled Study of Cidofovir Gel for Human Papillomavirus (HPV)-Associated Genital Warts. Poster presented at the 11th International Conference on Antiviral Research, San Diego, California, April 5-10. 1998;. Abstract #27.
12. Zabawski E.J. Jr, Sands B., Goetz D., et al. Treatment of verruca vulgaris with topical cidofovir. [letter] JAMA. 278:1997;1236.
13. Kedes D.H., Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest. 99:1997;2082-2086.
14. Medveczky M.M., Horvath E., Lund T., et al. In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus. AIDS. 11:1997;1327-1332.
15. Neyts J., De Clercq E. Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother. 41:1997;2754-2756.
16. Hammoud Z., Parenti D.M., Simon G.L. Abatement of cutaneous Kaposi's sarcoma associated with cidofovir treatment. Clin Infect Dis. 26:1998;1233.
17. Simonart T., Noel J.C., De Dobbeleer G., et al. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir report of a case . J Med Virol. 55:1998;215-218.
18. Meadows K.P., Tyring S.K., Pavia A.T., et al. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol. 133:1997;987-990.
19. Davies E.G., Thrasher A., Lacey K., et al. Topical cidofovir for severe molluscum contagiosum. [letter] Lancet. 353:1999;2042.
20. Zabawski E.J. Jr, Cockerell C.J. Topical cidofovir for molluscum contagiosum in children. [letter] Pediatr Dermatol. 16:1999;414-415.
21. De Clercq E., Holy A. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine in various models of herpes simplex virus infection in mice. Antimicrob Agents Chemother. 35:1991;701-706.
22. Snoeck R., Andrei G., Gerard M., et al. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). Clin Infect Dis. 18:1994;570-578.
23. Lateef F., Don P.C., Kaufmann M., et al. Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS. [letter] Arch Dermatol. 134:1998;1169-1170.
24. Lalezari J., Schacker T., Feinberg J., et al. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. J Infect Dis. 176:1997;892-898.
25. Sacks S.L., Shafran S.D., Diaz-Mitoma F., et al. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes. Antimicrob Agents Chemother. 42:1998;2996-2999.
26. Hengge U.R., Goos M., Arndt R. Topical treatment of warts and mollusca with imiquimod. Ann Intern Med. 132:2000;95.
27. Hengge U.R., Esser S., Schultewolter T., et al. M Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol. 143:2000;1026-1031.
28. Sparling J.D., Checketts S.R., Chapman M.S. Imiquimod for plantar and periungual warts. Cutis. 68:2001;397-399.
29. Muzio GF, Massone C, Rebora A. Imiquimod and Common Warts: Occlusive Medication Improves its Efficacy (in press).
30. Weisshaar E., Gollnick H. Potentiating effect of imiquimod in the treatment of verrucae vulgares in immunocompromised patients. Acta Derm Venereol. 80:2000;306-307.
31. Barba A.R., Kapoor S., Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of Molluscum contagiosum in children. Dermatol Online J. 7:2001;20.
32. Strauss R.M., Doyle E.L., Mohsen A.H., et al. Successful treatment of molluscum contagiosum with topical imiquimod in a severely immunocompromised HIV-positive patient. Int J STD AIDS. 12:2001;264-266.
33. Liota E., Smith K.J., Buckley R., et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg. 4:2000;76-82.
34. Skinner R.B. Jr, Ray S., Talanin N.Y. Treatment of molluscum contagiosum with topical 5% imiquimod cream. Pediatr Dermatol. 17:2000;420.
35. Syed T.A., Goswami J., Ahmadpour O.A., et al. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream a placebo-controlled, double-blind study . J Dermatol. 25:1998;309-313.
36. Brown C.W. Jr, O'Donoghue M., Moore J., et al. Recalcitrant molluscum contagiosum in an HIV-afflicted male treated successfully with topical imiquimod. Cutis. 65:2000;363-366.
37. Buckley R., Smith K. Topical imiquimod therapy for chronic giant molluscum contagiosum in a patient with advanced human immunodeficiency virus 1 disease. Arch Dermatol. 135:1999;1167-1169.
38. Hannuksela-Svahn A., Nordal E., Christensen O. Treatment of multiple basal cell carcinomas in the scalp with imiquimod 5% cream. Acta Derm Venereol. 80:2000;381-382.
39. Kagy M.K., Amonette R. The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell nevus syndrome patient. Dermatol Surg. 26:2000;577-578. discussion 578-9.
40. The Australasian Multicentre Trial Group, Marks R., Gebauer K., Shumack S., et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 44:2001;807-813.
41. Beutner K.R., Geisse J.K., Helman D., et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 41:1999;1002-1007.
42. Cerburkovas O., Krause M., Ulrich J., et al. [Disseminated actinic keratoses. Comparison of topical photodynamic therapy with 5-aminolevulinic acid and topical 5% imiquimod cream]. Hautarzt. 52:2001;942-946. [MEDLINE summary].
43. Stockfleth E., Meyer T., Benninghoff B., et al. Successful treatment of actinic keratosis with imiquimod cream 5% a report of six cases . Br J Dermatol. 144:2001;1050-1053.
44. Thai K.-E., Sinclair R.D. Treatment of Bowen's disease of the penis with imiquimod. J Am Acad Dermatol. 46:2002;470.
45. Cook-Bolden F., Weinberg J.M. Topical imiquimod 5% cream in the treatment of Bowen's disease of the penis. J Am Acad Dermatol. 46:2002;146.
46. Pehoushek J., Smith K.J. Imiquimod and 5% fluorouracil therapy for anal and perianal squamous cell carcinoma in situ in an HIV-1-positive man. Arch Dermatol. 137:2001;14-16.
47. Schroeder T.L., Sengelmann R.D. Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol. 46:2002;545-548.
48. Smith K.J., Germain M., Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imiquimod 5% cream and a COX inhibitor, sulindac potential applications for this combination of immunotherapy . Dermatol Surg. 27:2001;143-146.
49. Mackenzie-Wood A., Kossard S., de Launey J., et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol. 44:2001;462-470.
50. Smith K.J., Germain M., Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg. 27:2001;561-564.
51. Agarwal S., Berth-Jones J. Porokeratosis of Mibelli successful treatment with 5% imiquimod cream . Br J Dermatol. 146:2002;338.
52. Stockfleth E., Rowert J., Arndt R., et al. Detection of human papillomavirus and response to topical 5% imiquimod in a case of stucco keratosis. Br J Dermatol. 143:2000;846-850.
53. Buates S., Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463 efficacy and mode of action . J Infect Dis. 179:1999;1485-1494.
54. Arevalo I., Ward B., Miller R., et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis. 33:2001;1847-1851.
55. Ahmed I., Berth-Jones J. Imiquimod a novel treatment for lentigo maligna . Br J Dermatol. 143:2000;843-845.
56. Steinmann A., Funk J.O., Schuler G., et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 43:2000;555-556.
57. Townsend B.L., Cohen P.R., Duvic M. Zidovudine for the treatment of HIV-negative patients with psoriasis a pilot study . J Am Acad Dermatol. 32:1995;994-999.
58. Mallon E. Retroviruses and psoriasis. Curr Opin Infect Dis. 13:2000;103-107.